Other OTC - Delayed Quote USD

Candriam Equities L Oncology Impact (0P0001F59D)

145.98 +2.56 (+1.78%)
As of April 23 at 4:00 PM EDT. Market Open.

Top 10 Holdings (54.45% of Total Assets)

SymbolCompany% Assets
MRK
Merck & Co., Inc. 9.30%
AZN.L
AstraZeneca PLC 7.67%
NOVN.SW
Novartis AG 6.46%
ROG.SW
Roche Holding AG 5.47%
SHL.F
Siemens Healthineers AG 5.24%
HOLX
Hologic, Inc. 4.88%
TMO
Thermo Fisher Scientific Inc. 4.58%
REGN
Regeneron Pharmaceuticals, Inc. 4.41%
DHR
Danaher Corporation 3.34%
GILD
Gilead Sciences, Inc. 3.11%

Sector Weightings

Sector0P0001F59D
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Cash 6.07%
Stocks 93.92%
Bonds 0.00%
Others 0.00%
Preferred 0.00%
Convertible 0.00%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average 0P0001F59D Category Average
Price/Earnings 0.03 --
Price/Book 0.22 --
Price/Sales 0.21 --
Price/Cashflow 0.05 --
Median Market Cap 58,153.58 --
3 Year Earnings Growth 2.52 --

Bond Holdings

Performance & Risk

YTD Return 0.00%
5y Average Return 0.00%
Rank in Category (ytd) 38
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.99
Morningstar Risk Rating

Fund Overview

Category --
Fund Family Candriam
Net Assets --
YTD Return 7.20%
Yield 0.00%
Morningstar Rating
Inception Date Jul 30, 2021

Fund Summary

Related Tickers